CSPC Pharma climbs as FDA approves RSV vaccine clinical trials in US
26/08/2026 08:52
BUZZ-CSPC Pharma climbs as FDA approves RSV vaccine clinical trials in US ** Shares of CSPC Pharmaceutical Group 1093.HK climb 6.1% to HK$9.98, their highest level since August 20
** CSPC said U.S. Food and Drug Administration (FDA) has approved the company's recombinant respiratory syncytial virus (RSV) vaccine (SYS6057) - a Class 1 new preventive biological product, to conduct clinical trials in the U.S.
** The product also obtained China's National Medical Products Administration (NMPA) approval to conduct clinical trials
** YTD, stock up 13.4%, Hang Seng Biotech Index .HSBIO up 14.1%
(Reporting by Donny Kwok)
Recent news on CSPC PHARMACEUTICAL
See all newsBrief: CSPC Pharmaceutical Posts CSPC Innovation Pharmaceutical 9M Net Profit Attributable RMB 1.21 Billion
Brief: CSPC Pharmaceutical Publishes Updated Phase III OS Results For Anbenitamab In Her2-Positive Advanced Gastric Cancer
Brief: CSPC Pharmaceutical Says Batoclimab Injection (Enlida) Obtains Drug Registration Certificate From NMPA
Brief: CSPC Pharmaceutical Initiates Phase III Trial Of SYS6043 For Triple-Negative Breast Cancer In China
Factbox: Pharma sector doubles down on AI to slash costs, timelines